Albany, NY -- (SBWIRE) -- 11/14/2018 -- The global hospital infection therapeutics market will grow at a sluggish pace between 2018 and 2026, finds a report, titled "Hospital Infection Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 – 2026." The report offers a holistic study on the various factors supporting as well as inhibiting growth in the global hospital infection therapeutics market. It is currently available for sale on ResearchMoz.us.
According to the report, longer hospital stays and high treatment cost of bacterial infections will support the market's expansion between 2018 and 2026. The demand for hospital infection therapeutics is also expected to rise due to difficulties in the treatment of various infections owing to the presence of several co-morbidities. The report touts Europe as the leading region in the global market. The regions boasts a strong brand presence of some of the most prominent names in the industry with established distribution channels. This has created growth opportunities for the hospital infection therapeutics market in Europe.
Furthermore, the market is likely to witness growth opportunities in Asia Pacific over the course of the forecast period. Factors such as increasing geriatric population and the willingness of people to spend on advanced healthcare are supporting the market's expansion in Asia Pacific. Also the rising incidence of hospital acquired infections will fuel the demand for hospital infection therapeutics in the region.
Get a Sample PDF: https://www.researchmoz.us/enquiry.php?type=S&repid=1916535
In the coming years, the hospital infection therapeutics market will gain from the rising incidence of resistance bacterial infections. Besides this, funding from public and private players aimed at curbing the incidence of hospital acquired infections will boost the market. Furthermore, the market is forecast to gain from the rising research and development initiatives by leading market participants. A key point to consider here is that several agencies are funding these researches to encourage the development of novel antibiotics and improved therapeutic treatments. Driven by this factor, the global hospital infection therapeutic market will exhibit growth at an impressive pace.
In terms of therapeutics, the global hospital infection therapeutics market can be segmented into anti-fungal drugs, anti-bacterial drugs, anti-viral drugs, and others. Of these, the anti-bacterial segment is forecast to hold the leading share in the global market over the forecast period. The presence of a strong product pipeline aimed at addressing gaps in treatment will enable the segment to expand at a steady pace. According to the report, the anti-viral segment will also offer lucrative growth prospects to the market.
According to the report, Europe and North America held the leading share in the global market in 2017. Growth witnessed in these regions is supported by the greater market penetration, better affordability of people, favorable reimbursement policies, and higher per capita healthcare spending.
Some of the leading companies operating in the global hospital infection therapeutics market are GlaxoSmithKline plc, Merck & Co., Inc., Johnson & Johnson Services, AstraZeneca, Inc., F. Hoffmann-La Roche Ltd., Pfizer, Inc., Bayer AG, Gilead Sciences, Inc., and Allergan plc.
Contact Us:
Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG